Cathay Biotech is a global technology leader in synthetic biology and the use of bio-processes to produce new materials on an industrial scale. Cathay's long chain diacids are a perfect example demonstrating the potential for bio-manufacturing to commercially displace traditional chemical processes. Cathay also developed and became the first commercial producer of pentanediamine from renewable materials. Having the two key monomers to produce polyamides, Cathay also is a global innovator in the commercialization of new and unique renewable polyamides for the engineering polymer and textile markets. The series of bio-based polyamide products cover a wide range of new material with melting point from 130℃ to 315℃.
As a game-changing production technology, bio-production starts with biomass and other raw materials for biological conversion to higher value products. The nature of bio-production requires environmentally friendly and mild conditions that are inherently economical. The goal of Cathay's synthetic biology development programs is to address the excessive dependence of humans on traditionally produced chemicals as well as the subsequent environmental damage and worker safety issues associated with their production.
Cathay's headquarters and R&D are located at Zhangjiang Hi-Tech park in Shanghai and the two production sites are in Jinxiang and Wusu, P.R.China. The third production site is in construction process in Taiyuan, also in China, which will expand the capacity of current 75KT/a long chain diacids, 50KT/a pentanediamine and 100KT bio-based polyamides to much larger scale.
|Full name||Cathay Biotech Inc.|
|Founded||Nov 24th 2000|
|Listing||Aug 12th 2020|
|STAR Theme||New Materials|
|CSRCSector||Bio-based Material Manufacture|
|Has weighted voting rights structure?||No|
|Earnings Per Share||1.32||-||-|
|R&D expenditure as a % of operating revenue||4.71%||4.92%||4.74%|
|Total Owners' Equity||4,641.86||3,156.74||2,196.81|
|Net Cash Flows-Operating||359.62||-10.29||53.45|
|Net Cash Flows-Investing||-1,206.72||-587.60||-1,000.51|
|Net Cash Flows-Financing||1,050.43||645.10||715.39|
|Name||No. of Shares Held (mn)||% of Shares Held|
|Cathay Industrial Biotech Ltd.||118.00||28.32%|
|HBM Healthcare Investments (Cayman) Ltd.||29.61||7.11%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.